Journal
NATURE BIOTECHNOLOGY
Volume 34, Issue 4, Pages 430-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.3461
Keywords
-
Categories
Funding
- Walker Immunotherapy Fellowship
- Fred Hutchinson Cancer Research Center (FHCRC) Synergy Technology Fund
- National Institute of Health (NIH) grants [CA136551, CA114536, P50 CA138293]
Ask authors/readers for more resources
Adoptive immunotherapy with genetically engineered T cells has the potential to treat cancer and other diseases. The introduction of Strep-tag II sequences into specific sites in synthetic chimeric antigen receptors or natural T-cell receptors of diverse specificities provides engineered T cells with a marker for identification and rapid purification, a method for tailoring spacer length of chimeric receptors for optimal function, and a functional element for selective antibodycoated, microbead-driven, large-scale expansion. These receptor designs facilitate cGMP manufacturing of pure populations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval of transferred cells for downstream research applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available